693 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AMGN Amgen Inc. $200.81 $129.98B N/A
Article Searches
Merck Gets CHMP Nod for Six-Week Dosing Option of Keytruda http://www.zacks.com/stock/news/357700/merck-gets-chmp-nod-for-six-week-dosing-option-of-keytruda?cid=CS-ZC-FT-357700 Mar 05, 2019 - Merck (MRK) gets CHMP recommendation for a six-week dosing schedule of Keytruda across all current monotherapy indications.
AbbVie Gets CHMP Nod for Psoriasis Candidate Risankizumab http://www.zacks.com/stock/news/357598/abbvie-gets-chmp-nod-for-psoriasis-candidate-risankizumab?cid=CS-ZC-FT-357598 Mar 04, 2019 - AbbVie (ABBV) gets positive opinion of the CHMP recommending marketing approval for risankizumab for the treatment of moderate-to-severe plaque psoriasis.
Spectrum (SPPI) Misses Earnings Estimates in Q4, Tops Sales http://www.zacks.com/stock/news/357418/spectrum-sppi-misses-earnings-estimates-in-q4-tops-sales?cid=CS-ZC-FT-357418 Mar 01, 2019 - Spectrum Pharma (SPPI) misses bottom-line estimates in the fourth quarter but beats on revenues.
Roche (RHHBY) to Acquire Spark Therapeutics for $4.8 Billion http://www.zacks.com/stock/news/356763/roche-rhhby-to-acquire-spark-therapeutics-for-%2448-billion?cid=CS-ZC-FT-356763 Feb 25, 2019 - Roche (RHHBY) to acquire Philadelphia-based gene therapy company, Spark Therapeutics, Inc. (ONCE) at a price of $114.50 per share in an all-cash transaction.
Amgen Starts Phase III Enrollment for Heart Failure Drug http://www.zacks.com/stock/news/356653/amgen-starts-phase-iii-enrollment-for-heart-failure-drug?cid=CS-ZC-FT-356653 Feb 22, 2019 - Amgen (AMGN) and partners started enrollment for the second phase III study of omecamtiv mecarbil, which is being developed for the potential treatment of heart failure with reduced ejection fraction.
The Zacks Analyst Blog Highlights: Walmart, Amgen, Honda, TransCanada and TransUnion http://www.zacks.com/stock/news/355997/the-zacks-analyst-blog-highlights-walmart-amgen-honda-transcanada-and-transunion?cid=CS-ZC-FT-355997 Feb 21, 2019 - The Zacks Analyst Blog Highlights: Walmart, Amgen, Honda, TransCanada and TransUnion
Merck Gets Priority Review for Keytruda in Third-Line SCLC http://www.zacks.com/stock/news/355982/merck-gets-priority-review-for-keytruda-in-third-line-sclc?cid=CS-ZC-FT-355982 Feb 21, 2019 - Merck's (MRK) sBLA looking for approval of Keytruda monotherapy for the third-line treatment of small cell lung cancer, a difficult-to-treat cancer, gets FDA's priority review.
Top Analyst Reports for Walmart, Amgen and Honda http://www.zacks.com/research-daily/215092/top-analyst-reports-for-walmart-amgen-and-honda?cid=CS-ZC-FT-215092 Feb 20, 2019 - Top Analyst Reports for Walmart, Amgen and Honda
Merck's Keytruda Fails to Meet Endpoint in Liver Cancer Study http://www.zacks.com/stock/news/355533/mercks-keytruda-fails-to-meet-endpoint-in-liver-cancer-study?cid=CS-ZC-FT-355533 Feb 20, 2019 - Merck's (MRK) Keytruda fails a phase III study in second-line advanced hepatocellular carcinoma (HCC). It gets FDA approval for the adjuvant treatment of patients with high-risk stage III melanoma.
Roche's (RHHBY) BLA for Lymphoma Drug Gets Priority Review http://www.zacks.com/stock/news/355489/roches-rhhby-bla-for-lymphoma-drug-gets-priority-review?cid=CS-ZC-FT-355489 Feb 19, 2019 - The FDA accepts Roche's (RHHBY) BLA for polatuzumab vedotin and NDAs for entrectinib, and grants Priority Review status to the applications.

Pages: 1234567891011...70

<<<Page 6>